CEL-SCI CORP Files 8-K
Ticker: CVM · Form: 8-K · Filed: Sep 17, 2024 · CIK: 725363
Sentiment: neutral
Topics: 8-k, filing, sec
TL;DR
CEL-SCI filed an 8-K on 9/17 for events on 9/16 - details pending.
AI Summary
CEL-SCI CORPORATION filed an 8-K on September 17, 2024, reporting an event on September 16, 2024. The filing pertains to "Other Events" and "Financial Statements and Exhibits" but does not provide specific details on these events within the provided text.
Why It Matters
This 8-K filing indicates that CEL-SCI CORPORATION has reported significant events or filed financial statements, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific operational or financial details that would indicate immediate risk.
Key Players & Entities
- CEL-SCI CORPORATION (company) — Registrant
- September 16, 2024 (date) — Earliest event reported
- September 17, 2024 (date) — Date of report
- 001-11889 (other) — Commission File Number
- 84-0916344 (other) — IRS Employer Identification No.
- Vienna, VA (location) — Principal executive offices
FAQ
What specific events are being reported under 'Other Events'?
The provided text does not specify the details of the 'Other Events' reported by CEL-SCI CORPORATION.
What financial statements or exhibits are being filed?
The filing indicates 'Financial Statements and Exhibits' are included, but the content of these is not detailed in the provided text.
What is the significance of the 'Date As Of Change' being September 16, 2024?
This date likely signifies the effective date of the events or information being reported in the 8-K filing.
What was CEL-SCI CORPORATION's former name and when did it change?
CEL-SCI CORPORATION was formerly known as INTERLEUKIN 2 INC, and the name change occurred on March 17, 1988.
Where are CEL-SCI CORPORATION's principal executive offices located?
The principal executive offices of CEL-SCI CORPORATION are located at 8229 Boone Blvd. #802, Vienna, VA 22182.
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-09-16 17:45:19
Filing Documents
- cvm_8k.htm (8-K) — 24KB
- cvm_ex99.htm (EX-99) — 20KB
- cvm_ex991img7.jpg (GRAPHIC) — 4KB
- cvm_ex991img5.jpg (GRAPHIC) — 4KB
- cvm_ex991img4.jpg (GRAPHIC) — 34KB
- 0001654954-24-011975.txt ( ) — 231KB
- cvm-20240916.xsd (EX-101.SCH) — 6KB
- cvm-20240916_lab.xml (EX-101.LAB) — 14KB
- cvm-20240916_cal.xml (EX-101.CAL) — 1KB
- cvm-20240916_pre.xml (EX-101.PRE) — 9KB
- cvm-20240916_def.xml (EX-101.DEF) — 2KB
- cvm_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 16, 2024, CEL-SCI Corporation (the "Company") issued a press release reporting new data from its concluded Phase 3 study of Multikine (Leukocyte Interleukin, Injection) were presented at the European Society for Medical Oncology (ESMO) 2024 Congress on Saturday, September 14, 2024 in a poster titled "Prognostic significance of diagnostic staging in treatment nave, resectable locally advanced primary oral cavity squamous cell carcinoma for neoadjuvant Leukocyte Interleukin Injection immunotherapy". This data is highly relevant to the Company's 212 patient confirmatory Registration Study which has received the U.S. Food and Drug Administration's (FDA) go-ahead and is currently under preparation.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99 Press Release re. ESMO 2024 poster results 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 16, 2024 CEL-SCI CORPORATION By: /s/ Patricia Prichep Patricia B. Prichep Senior Vice President of Operations 3